Red Violet Posts 20% Q4 Growth but Withholds Key Profitability Data

What happened

Red Violet reported Q4 2025 revenue of $23.4 million, a 20% year-over-year increase, and full-year revenue of $90.3 million with GAAP EPS of $0.91, continuing the ~20% growth trend highlighted in the DeepValue report. This performance aligns with the base-case scenario of sustained expansion driven by FOREWARN user growth and IDI customer adds, as noted in the report's investment thesis. However, the press release omits crucial details on adjusted EBITDA margins and contractual revenue mix, which the report identifies as essential for justifying the stock's premium valuation at a P/E of 51.1. Investors should be critical of this omission, as previous filings showed a modest slippage in contractual mix to 75% in Q3'25 and emphasized the need for margins above 35% to support the WAIT rating. Until the full earnings release provides clarity on profitability and revenue quality, the narrative remains incomplete, reinforcing the report's cautionary stance.

Implication

Red Violet's 20% revenue growth in Q4 supports the bullish narrative of ongoing adoption in real-estate and public-sector workflows, but without disclosed profitability metrics, investors cannot assess whether the high margins (e.g., 39% adjusted EBITDA in Q3'25) persist. The absence of contractual revenue mix data is particularly concerning, as the DeepValue report flagged a drop below 70% as a thesis-breaker that could increase cyclicality and erode valuation multiples. Thin trading liquidity, noted in the report, amplifies the risk of price swings if upcoming details reveal margin compression or mix deterioration, undermining the stock's premium pricing. Investors should monitor the full 10-K or earnings call for specifics on adjusted EBITDA and contractual share, with any shortfall likely prompting a re-rating toward the bear case implied value of $32. In the interim, the WAIT rating holds, suggesting patience for a pullback to $38 or confirmation of operational resilience to improve risk-adjusted entry.

Thesis delta

The Q4 results do not shift the investment thesis, as revenue growth aligns with the base case but critical profitability and mix metrics are unreported. The WAIT rating remains appropriate until further data validates that adjusted EBITDA margins exceed 35% and contractual revenue share stays near 75%, with no evidence yet of public-sector wins via the Carahsoft channel to de-risk the growth story.